Women's Lifestyle Physical Activity Program for African American Women: Fidelity Plan and Outcomes

J Phys Act Health. 2016 Oct;13(10):1100-1109. doi: 10.1123/jpah.2015-0701. Epub 2016 Aug 16.


Background: For interventions to be implemented effectively, fidelity must be documented. We evaluated fidelity delivery, receipt, and enactment of the 48-week Women's Lifestyle Physical Activity Program conducted to increase physical activity and maintain weight in African American women.

Methods: Three study conditions all received 6 group meetings; 1 also received 11 motivational interviewing personal calls (PCs), 1 received11 automated motivational message calls (ACs), and 1 received no calls. Group meeting delivery was assessed for adherence and competence. PC delivery was assessed with the Motivational Interviewing Treatment Integrity Code. Receipt was defined as group meeting attendance, completion of PCs, and listening to ACs. Enactment was number of weeks an accelerometer was worn.

Results: For group meeting delivery, mean adherence was 80.8% and mean competence 2.9 of 3.0. Delivery of PCs did not reach criterion for competence. Receipt of more than one-half the dose was achieved for 84.9% of women for group meetings, 85.5% for PCs, and 42.1% for ACs. Higher group meeting attendance was associated with higher accelerometer steps at 24 weeks and lower BMI at 24 and 48 weeks.

Conclusions: Fidelity measurement and examination of intervention delivery, receipt, and enactment are important to explicate conditions in which interventions are successful.

Trial registration: ClinicalTrials.gov NCT01700894.

Keywords: health behavior; health disparities; intervention study.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Black or African American*
  • Body Composition
  • Body Weight
  • Exercise*
  • Female
  • Health Promotion / methods*
  • Humans
  • Life Style*
  • Middle Aged
  • Motivation
  • Outcome Assessment, Health Care
  • Patient Compliance
  • Women's Health Services*

Associated data

  • ClinicalTrials.gov/NCT01700894